<code id='E9FDCF9067'></code><style id='E9FDCF9067'></style>
    • <acronym id='E9FDCF9067'></acronym>
      <center id='E9FDCF9067'><center id='E9FDCF9067'><tfoot id='E9FDCF9067'></tfoot></center><abbr id='E9FDCF9067'><dir id='E9FDCF9067'><tfoot id='E9FDCF9067'></tfoot><noframes id='E9FDCF9067'>

    • <optgroup id='E9FDCF9067'><strike id='E9FDCF9067'><sup id='E9FDCF9067'></sup></strike><code id='E9FDCF9067'></code></optgroup>
        1. <b id='E9FDCF9067'><label id='E9FDCF9067'><select id='E9FDCF9067'><dt id='E9FDCF9067'><span id='E9FDCF9067'></span></dt></select></label></b><u id='E9FDCF9067'></u>
          <i id='E9FDCF9067'><strike id='E9FDCF9067'><tt id='E9FDCF9067'><pre id='E9FDCF9067'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:Wikipedia    Page View:4123
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In